LEENO Industrial (058470) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
13 Nov, 2026Executive summary
9M 2026 revenue was ₩325.7bn, operating income ₩160.2bn and net income ₩128.9bn; all exceeded the prior-year 9M figures. Q3 revenue and net income were below prior-year Q3 levels.
Semiconductor test products accounted for 91.2% of 9M sales; IC test sockets were the largest category at 67.8%.
Financial highlights
9M revenue ₩325.7bn vs ₩287.8bn prior-year 9M; operating income ₩160.2bn vs ₩136.6bn; net income ₩128.9bn vs ₩112.4bn.
Q3 revenue was ₩82.7bn vs ₩96.8bn prior-year Q3; net income was ₩22.6bn vs ₩41.9bn.
9M EPS was ₩1,699 vs ₩1,481 prior-year; diluted EPS matched basic EPS as no dilutive potential ordinary shares were held.
9M operating cash flow was ₩142.4bn; investing cash outflow ₩53.0bn and financing cash outflow ₩60.8bn, including ₩60.7bn in dividends paid.
Outlook and guidance
A new factory and equipment investment of ₩97.2bn is intended to expand production capacity and R&D; ₩90.8bn was spent by Sept. 30, with completion timing revised to Nov. 30, 2026.
Semiconductor test demand is expected to benefit from AI, data centers and advanced devices; WSTS projected the global semiconductor market at US$1.51tn in 2026 and US$1.91tn in 2027.
Dividend policy targets a payout around 30% of net income, subject to earnings and distributable profits; the recent 3-year average payout ratio was 40%.
Latest events from LEENO Industrial
- Global semiconductor test leader with strong financials, innovation, and major tech clients.058470
Investor presentation - H1 2026 net income reached KRW 106.32 billion on KRW 242.96 billion revenue, with zero debt.058470
Q2 2026 - Q1 2025 delivered strong profits, robust exports, and a debt-free position, with major facility investment.058470
Q1 2025 - Revenue and profit rose, margins remained high, and major expansion was funded internally.058470
Q4 2024 - H1 2025 net income was KRW 70.5B on KRW 190.9B revenue, with zero debt and robust exports.058470
Q2 2025 - H1 2024 net income margin exceeded 40% on ₩125.8B sales, with zero debt and strong exports.058470
Q2 2024 - Revenue and profit surged on strong semiconductor and medical device demand, with zero debt.058470
Q4 2025 - 2024 Q3 YTD revenue and profit fell, but zero debt and robust R&D support future growth.058470
Q3 2024 - Q1 2026 delivered robust growth, high profitability, and zero debt, with strong export sales.058470
Q1 2026